DNA aptamer evolved by cell-SELEX for recognition of prostate cancer

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Wang, Yuanyuan ^a   Luo, Yun ^a   Bing, Tao ^b   Chen, Zheng ^a   Lu, Minhua ^a   Zhang, Nan ^b   Shangguan, Dihua ^b   Gao, Xin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b INSTITUTE OF CHEMISTRY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; DNA APTAMER WY 5A; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER DIAGNOSIS; CANCER GROWTH; CELL SPECIFICITY; COMBINATORIAL CHEMISTRY; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISSOCIATION CONSTANT; DNA PROBE; EARLY DIAGNOSIS; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERNALIZATION; MALE; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATE HYPERTROPHY; PROTEIN BINDING; CHEMISTRY; METABOLISM; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

APTAMERS, NUCLEOTIDE; CELL LINE, TUMOR; HUMANS; MALE; PROSTATIC NEOPLASMS; SELEX APTAMER TECHNIQUE;

EID: 84903535780     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100243     Document Type: Article

References (45)

1. World Health Organization (2008) World Cancer Report. IARC Press. 450 p.
2. Xia SJ, Cui D, Jiang Q (2012) An overview of prostate diseases and their characteristics specific to Asian men. Asian J Androl 14:458-64.
3. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11-30.
4. Sim HG, Cheng CW (2005) Changing demography of prostate cancer in Asia. Eur J Cancer 41:834-45. (Pubitemid 40467547)
5. Damber JE, Aus G (2008) Prostate cancer. Lancet 371:1710-21.
6. Lin GW, Yao XD, Zhang SL, Dai B, Ma CG, et al. (2009) Prostate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients. Asian J Androl 11:443-50.
7. Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, et al. (2003) The case for early detection. Nat Rev Cancer 3:243-52. (Pubitemid 37328860)
8. Guess HA, Heyse JF, Gormley GJ (1993) The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate 22:31-7. (Pubitemid 23075491)
9. Tchetgen MB, Song JT, Strawderman M, Jacobsen SJ, Oesterling JE (1996) Ejaculation increases the serum prostate-specific antigen concentration. Urology 47:511-6. (Pubitemid 26165978)
10. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, et al. (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320-8.
11. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, et al. (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360:1310-9.
12. Kanwar JR, Mohan RR, Kanwar RK, Roy K, Bawa R (2010) Applications of aptamers in nanodelivery systems in cancer, eye and inflammatory diseases. Nanomedicine (Lond) 5:1435-45.
13. Jayasena SD (1999) Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem 45:1628-50.
14. Breaker RR (2004) Natural and engineered nucleic acids as tools to explore biology. Nature 432:838-45.
15. Osborne SE, Matsumura I, Ellington AD (1997) Aptamers as therapeutic and diagnostic reagents: problems and prospects. Curr Opin Chem Biol 1:5-9. (Pubitemid 127435139)
16. Famulok M, Hartig JS, Mayer G (2007) Functional aptamers and aptazymes in biotechnology, diagnostics, andtherapy. Chem Rev 107:3715-43. (Pubitemid 47534316)
17. Navani NK, Li Y (2006) Nucleic acid aptamers and enzymes as sensors. Curr Opin Chem Biol 10:272-81. (Pubitemid 43815779)
18. Jiang Y, Zhu C, Ling L, Wan L, Fang X, et al. (2003)Specific aptamer-protein interaction studied by atomic force microscopy. Anal Chem 75:2112-6. (Pubitemid 36542352)
19. Chen HW, Medley CD, Sefah K, Shangguan D, Tang Z, et al. (2008) Molecular recognition of small-cell lung cancer cells using aptamers. ChemMedChem 3:991-1001.
20. Ellington AD, Szostak JW (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 346:818-22.
21. Wessels JT, Busse AC, Mahrt J, Dullin C, Grabbe E, et al. (2007) In vivo imaging in experimental preclinical tumor research-a review. Cytometry A 71:542-9. (Pubitemid 47221716)
22. Keefe AD, Pai S, Ellington A (2010) Aptamers as therapeutics. Nat Rev Drug Discov. 9:537-50.
23. Tuerk C, Gold L (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505-10.
24. Shangguan D, Li Y, Tang Z, Cao ZC, Chen HW, et al. (2006) Aptamers evolved from live cells as effective molecular probes for cancerstudy. Proc Natl Acad Sci U S A 103:11838-43. (Pubitemid 44215773)
25. Xiao Z, Shangguan D, Cao Z, Fang X, Tan W (2008) Cell-specific internalization study of an aptamer from whole cell selection. Chemistry 14:1769-75.
26. Shangguan D, Meng L, Cao ZC, Xiao Z, Fang X, et al. (2008) Identification of liver cancer-specific aptamers using whole live cells. Anal Chem 80:721-8. (Pubitemid 351206860)
27. Zhang K, Sefah K, Tang L, Zhao Z, Zhu G, et al. (2012) A novel aptamer developed for breast cancer cell internalization. ChemMedChem 7:79-84.
28. Kanwar JR, Roy K, Kanwar RK (2011) Chimeric aptamers in cancer cell-targeted drug delivery. Crit Rev Biochem Mol Biol 46:459-77.
29. Bing T, Yang X, Mei H, Cao Z, Shangguan D (2010) Conservative secondary structure motif of streptavidin-binding aptamers generated by different laboratories. Bioorg Med Chem 18:1798-805.
30. Yang X, Bing T, Mei H, Fang C, Cao Z, et al. (2011) Characterization and application of a DNA aptamer binding to L-tryptophan. Analyst 136:577-85.
31. Shangguan D, Tang Z, Mallikaratchy P, Xiao Z, Tan W (2007) Optimization and modifications of aptamers selected from live cancer cell lines. Chembiochem 8:603-6. (Pubitemid 47194848)
32. Zuker M (2003) Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31:3406-15.
33. Rimmele M (2003) Nucleic acid aptamers as tools and drugs: recent developments. Chembiochem 4:963-71.
34. Patil SD, Rhodes DG, Burgess DJ (2005) DNA-based therapeutics and DNA delivery systems: a comprehensive review. AAPS 7:E61-77. (Pubitemid 41554297)
35. Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, et al. (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum. Pathol 31:578-83. (Pubitemid 30323983)
36. Pulukuri SM, Gondi CS, Lakka SS, Jutla A, Estes N, et al. (2005). RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 280: 36529-40. (Pubitemid 41633927)
37. Kovar JL, Johnson MA, Volcheck WM, Chen J, Simpson MA (2006) Hyaluronidase expression induces prostate tumor metastasis in an orthotopic mouse model. Am J Pathol 169(4):1415-26. (Pubitemid 351194374)
38. Montironi R, Mazzuccheli R, Scarpelli M, Lopez-Beltran A, Fellegara G, et al. (2005) Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance and sources of pathology discrepancies. BJU Int 95:1146-52. (Pubitemid 40799472)
39. Alberti C (2013) Taxane- and epothilone-based chemotherapy: from molecule cargo cytoskeletal logistics to management of castration-resistant prostate carcinoma. Eur Rev Med Pharmacol Sci 17:1658-64.
40. Zhou J, Rossi JJ (2011) Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides 21:1-10.
41. Min K, Jo H, Song K, Cho M, Chun YS, et al. (2011) Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers. Biomaterials 32:2124-32.
42. Sefah K, Shangguan D, Xiong X, O'Donoghue MB, Tan W (2010) Development of DNA aptamers using Cell-SELEX. Nat Protoc 5:1169-85.
43. Zhao Z, Xu L, Shi X, Tan W, Fang X, et al. (2009) Recognition of subtype non-small cell lung cancer by DNA aptamers selected from living cells. Analyst 134:1808-14.
44. Robertson D, Savage K, Reis-Filho JS, Isacke CM (2008) Multiple immunofluorescence labelling of formalin-fixed paraffin-embedded (FFPE) tissue. BMC Cell Biol. 9:13.
45. Gown AM (2008) Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 21 Suppl 2:S8-15.